MedicaidCoverageMedium impact
KMAP BULLETIN: Preferred Drug List Update – October 2025
Kansas Medicaid (KanCare)·KS · Allergy & Immunology, Rheumatology, Pulmonology +2 more·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 21, 2026
Summary
Kansas Medicaid is moving several specialty medications from preferred to non-preferred status (Nucala, Xolair, Humira) while making Fasenra preferred, effective October 1, 2025. This will likely require prior authorization for the non-preferred drugs and may affect patient access.
Action Required
Before October 1, 2025: Billing team must update prior authorization workflows for Nucala (mepolizumab), Xolair (omalizumab), and Humira (adalimumab) as these will require prior auth as non-preferred drugs. Update medication lists to show Fasenra (benralizumab) as preferred. Monitor KanCare MCO implementation dates as they may vary from the state effective date.